Patent ID: 8725426

Claim:
A method of predicting a likelihood of a clinical outcome for a patient with prostate cancer, comprising: (a) measuring levels of RNA transcripts of the following genes: BGN, COL1A1, SFRP4, FLNC, GSN, TPM2, GSTM2, FAM13C, KLK2, AZGP1, SRD5A2, and TPX2, in a biological sample containing cancer cells obtained from the patient; (b) normalizing the level of the RNA transcripts to obtain normalized gene expression levels; (c) calculating a quantitative score for the patient, wherein the quantitative score (QS) is calculated as follows: QS= 0.735 ×ECM (Stromal Response) group score −0.368×Migration (Cellular Organization) group score −0.352×PSA (Androgen) group score +0.095×Proliferation ( TPX 2) score, wherein ECM (Stromal Response) group score=0.527 ×BGN+ 0.457 ×COL 1 A 1+0.156 ×SFRP 4 Migration (Cellular Organization) group score=0.163 ×FLNC+ 0.504 ×GSN+ 0.421 ×TPM 2+0.394 ×GSTM 2 PSA (Androgen) group score=0.634 ×FAM 13 C+ 1.079 ×KLK 2+0.642 ×AZGP 1+0.997 ×SRD 5 A 2 Threshold score Proliferation ( TPX 2) score= TPX 2 Threshold score, wherein SRD ⁢ ⁢ 5 ⁢ ⁢ A ⁢ ⁢ 2 ⁢ ⁢ Threshold ⁢ ⁢ Score = { 5.5 if ⁢ ⁢ ⁢ SRD ⁢ ⁢ 5 ⁢ A2 < 5.5 SRD ⁢ ⁢ 5 ⁢ A ⁢ ⁢ 2 otherwise ⁢ ⁢ and ⁢ ⁢ TPX ⁢ ⁢ Threshold ⁢ ⁢ Score = { 5.0 if ⁢ ⁢ TPX ⁢ ⁢ 2 < 5.0 TPX ⁢ ⁢ 2 otherwise , ⁢ ⁢ and wherein the gene symbols in the equations represent the normalized gene expression levels of the RNA transcripts of the respective genes; and (d) predicting the likelihood of a clinical outcome for the patient based on the quantitative score.